Atom Therapeutics Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific Advisory Board

PRESS RELEASE

Atom Therapeutics Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific Advisory Board

Jiangsu, China—April 3, 2023 – Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the addition of Robert Terkeltaub, M.D., Professor of Medicine Emeritus at University of California at San Diego and an expert in inflammation and gout to its Scientific Advisory Board.

“We are very pleased to have Dr. Terkeltaub join our Scientific Advisory Board,” said Atom Founder, CEO, President and Chairman William Shi, Ph.D. “His outstanding research in rheumatology and gout will be invaluable as we move our pipeline forward to help chronic gout patients who now have limited effective treatments.”

Atom’s lead product, ABP-671, is an oral, small molecule URAT1 inhibitor for treatment of chronic gout. The drug is designed to reduce excessive levels of uric acid in the blood, a condition called hyperuricemia, which is the cause of gout and its characteristic painful and debilitating flare-ups. In two recent Phase 2a trials, ABP-671 was well tolerated and reduced uric acid levels below the threshold for hyperuricemia. The company has met with the U.S. Food and Drug Administration and expects to enter a Phase 2b/3 clinical trial soon.

“I look forward to being part of the Atom Therapeutics team,” said Dr, Terkeltaub. “Gout is a major and growing public health problem in many parts of the world. There is a pressing unmet need for safe and effective new treatment options . Atom’s program has demonstrated the potential to lead to a novel, highly potent, and valuable treatment.”

Dr. Terkeltaub received his medical degree at McGill University in Montreal, Canada, and completed McGill-based residency and training programs at Montreal General Hospital in Rheumatology and Internal Medicine. Dr. Terkeltaub has been the recipient of numerous teaching awards at the University of California at San Diego. His research has concentrated principally on inflammation and skeletal biology and the interfaces between the two as well as osteoarthritis, gout and CPPD crystal deposition disease, and arterial diseases pertinent to rheumatology.

Gout is one of the most common types of inflammatory arthritis affecting well over 40 million people worldwide. The disease has a large and growing patient population in not only in the U.S., where it affects over 10 million adults, but also Europe, Asia and Latin America. The painful gout flares, concentrated primarily in the joints of lower extremities, are promoted by failure to lower the level of uric acid in the blood to below 6 mg/dL. Failure to maintain healthy levels of uric acid can cause permanent joint damage and may contribute to other medical illnesses that commonly afflict patients with gout.

Atom’s Scientific Advisory Board also includes Kenneth Saag, M.D., Professor at the Department of Medicine, Division of Clinical Immunology and Rheumatology at University of Alabama at Birmingham; N. Lawrence Edwards, M.D., Vice Chairman and Professor, Department of Medicine, University of Florida and Vibeke Strand, M.D. Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine.

About Atom Therapeutics
Hangzhou Atom Therapeutics Co., Ltd., is a fast-growing innovative drug company focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in late stage clinical development for treatment of chronic gout. For more information please visit: https://atombp.us/.